Lilly and its manufacturing partner Resilience are putting $750 million into an Ohio campus to make more of the injector pens behind the diabetes and obesity boom -- 400 new jobs, full operations by early 2027.
DeepSeek's V4 Flash 0731 scored 50 on the Artificial Analysis Intelligence Index at $0.14/$0.28 per million tokens — one point behind GPT-5.6 Luna and cheaper on both ends.
Spur Intelligence bootstrapped for nine years mapping the internet's shadow traffic. Now Insight Partners has handed the roughly 40-person bot-detection shop $200 million — as bots quietly overtake humans online.
Celcuity's first FDA drug, REVTORPYK, cut breast-cancer progression risk 76% and stretched median control from 2.0 to 9.3 months — yet the stock slid on a delayed launch and rough side effects.
Nvidia is reportedly investing $5 billion in Ilya Sutskever's Safe Superintelligence — a two-year-old lab with no product, now valued at $32 billion — for a stake and access to Vera Rubin.
Socure raised $156M at a $5.2B valuation and bought agentic-AI startup Fravity to fight machine-speed fraud with AI agents of its own.
🔥 Gigabyte Just Dropped a $400 WOLED Gaming Monitor and It Changes Everything...
The AI chip company Cerebras Systems — the most prominent challenger to Nvidia's GPU empire — hit the Nasdaq on Thursday under the ticker CBRS and...
> In 2025, startups discovered AI. In 2026, the winners figured out which tools to use and when. Here's the stack the smartest founders are runni...
Bending Spoons is buying Airtable for $1.285 billion in all cash — about 89% below the productivity startup's $11.7B pandemic-era peak, and its first deal since going public.
The FDA cleared Revolution Medicines' daraxonrasib, the first broad RAS-targeted pill for metastatic pancreatic cancer, doubling median survival to 13.2 months at a $477,000-a-year list price.
The FDA cleared GENGLYCOS, Ultragenyx's first gene therapy: a one-time $2.7 million infusion targeting the root cause of glycogen storage disease type Ia.
AusperBio raised $120M to push AHB-137, an antisense drug that cleared hepatitis B in 68% of a small trial, toward the first functional cure for a disease 240 million people live with.
